For the record, if you're sick, YOU have a responsibility--as a member of our society who chooses to live and interact in a community setting (as opposed to isolation somewhere far from others)--to do ALL that you can to ensure that whatever communicable disease you have, doesn't get passed on to anyone.
This not only means basic hygiene (frequent hand washing, coughing/sneezing into your elbow, etc.), but also full disclosure with anyone you may touch directly (e.g. shaking hands) or indirectly (touching something that someone else may touch afterwards).
Please, be considerate to others and recognize the fact that we all live together. Is there value in getting sick and building an immunity? Of course! But this will happen even with exceptional social hygiene, and we don't need to function as willing vectors in propagating some DNA of unknown origin.
Ok, now back to the program...
The FDA has announced it will review a new study recently published that shows patients taking azithromycin (Zithromax, one of the world's best-selling antibiotics) face a small increased risk for sudden cardiac death compared with patients taking amoxicillin, ciprofloxacin, (other types of antibiotics) or no antibiotic at all.
The observational study in question looked at patients receiving a 5-day course of azithromycin. The issue of these types of antibiotics increasing the risk for cardiovascular death has been on the FDA's radar since last year. In March, the FDA revised the warnings section of an extended-release, oral suspension version of azithromycin (Zmax) to mention reports of QT-interval prolongation and "torsades de pointes" and advised doctors to avoid prescribing the antibiotic for patients with known QT-interval prolongation, patients with low potassium levels, or those taking drugs that prolong the QT interval.
QT-interval prolongation can trigger an abnormal and sometimes fatal heart arrhythmia (called torsades de pointes), and has also been linked to other antibiotic drugs in its class. This class, called macrolides, also includes clarithromycin (Biaxin) and erythromycin--labels for both of these also mention QT-interval prolongation. The FDA will be revising the labels of other macrolides in a similar fashion.
- FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death
- Azithromycin and the Risk of Cardiovascular Death
- Proton Pump Inhibitors Increase Risk of Hip Fractures
- Proton Pump Inhibitors Linked to Pneumonia
- Statin Drugs for Cholesterol Increase the Risk of Diabetes
- Dabigatran May Cause More Deaths than Warfarin
- Diabetic Drug Increases Risk of Bladder Cancer
- Bisphosphonates Linked to Kidney Damage & Death
Click HERE to subscribe to Know Guff by email